Regulus Therapeutics (NASDAQ:RGLS) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 65.22 percent increase over losses of $(0.23) per share from the same period last year.
Keybanc Maintains Overweight on Twitter, Lowers Price Target to $40
Keybanc analyst Justin Patterson maintains Twitter (NYSE:TWTR) with a Overweight and lowers the price target from $70 to $40.
